431 completed. 431 Phase 2, 47 Phase 1, 35 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 431 | Completed 431 |
| Phase 1 | 47 | Completed 47 |
| Phase 3 | 35 | Completed 35 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fisetin in Mild Alzheimer's Disease Fisetin - Alzheimer s Disease, Alzheimer Dementia | Phase 2 | Completed | Sunnybrook Health Sciences Centre | 5 | 2026-01-27 | 2026-08-20 |
| A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease ONO-2020, Placebo - Alzheimer Disease | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 260 | 2025-04-24 | 2026-10-22 |
| A Study of NTRX-07 in Participants With Alzheimer's Disease NTRX-07, Placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 2 | Completed | NeuroTherapia, Inc. | 48 | 2025-03-01 | 2026-10-29 |
| A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients EI-1071 tablet, oral - Mild, Moderate, or Severe Alzheimer's Disease | Phase 2 | Completed | Elixiron Immunotherapeutics Inc. | 7 | 2024-12-16 | 2026-09-23 |
| Daridorexant to Prevent Delirium After Heart Surgery Daridorexant 50 mg, Placebo - POSTOPERATIVE DELIRIUM, POSTOPERATIVE COGNITIVE DECLINE | Phase 2 | Completed | University of Rochester | 11 | 2024-11-11 | 2025-07-11 |
| Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill MAR - Alzheimer Disease | Phase 2 | Completed | Noah Pharmaceuticals, Inc. | 121 | 2024-10-16 | 2026-04-08 |
| Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation HiDO-ALZ - Alzheimer Disease, Dementia | Phase 2 | Completed | HiDO Technologies | 50 | 2024-09-05 | 2026-10-07 |
| A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease Mevidalen, Placebo - Alzheimer Disease | Phase 2 | Completed | Eli Lilly and Company | 304 | 2024-08-26 | 2026-06-18 |
| Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease Cannabis, Placebo - Alzheimer Disease | Phase 2 | Completed | Federal University of Latin American Integration | 72 | 2024-08-13 | 2025-05-25 |
| Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) PRI-002, Placebo - Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset | Phase 2 | Completed | PRInnovation GmbH | 304 | 2024-02-15 | 2026-07-10 |
| Life's End Benefits of cannaBidiol and tetrahYdrocannabinol T2:C100, Placebo - Agitation, Dementia | Phase 2 | Completed | University of Southern California | 120 | 2024-01-05 | 2026-09-02 |
| DMB-I in the Treatment of Alzheimer Type Dementia DMB-I (Dimebon), Placebo - Alzheimer Disease, Dementia of Alzheimer Type | Phase 2 | Completed | Bigespas LTD | 133 | 2023-12-27 | 2025-03-28 |
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
| Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 GV1001 Placebo, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 67 | 2023-12-12 | 2025-11-21 |
| PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS) RAVICTI 1.1 g/ml, Placebo - Corticobasal Syndrome (CBS) | Phase 2 | Completed | Technical University of Munich | 32 | 2023-12-12 | 2026-09-11 |
| Pharmacological Enhancement of Glymphatic Function in Humans Dexmedetomidine, Dexmedetomidine and Midodrine, Placebo - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Applied Cognition | 31 | 2023-12-11 | 2026-02-25 |
| Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography Sirolimus - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Karolinska Institutet | 14 | 2023-09-01 | 2025-07-03 |
| GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 78 | 2023-06-14 | 2026-02-10 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease ABBV-552, Placebo for ABBV-552 - Alzheimer's Disease (AD) | Phase 2 | Completed | AbbVie | 263 | 2023-06-05 | 2025-10-15 |
| Efficacy, Safety of Astragalus Membranaceus in Mild-to-Moderate Alzheimer's Disease Astragalus Membranaceus Root - Alzheimer Disease | Phase 2 | Completed | Fujian Medical University Union Hospital | 76 | 2023-05-01 | 2024-11-19 |
Showing 20 of 431. Sign in to see all of them.
Alzheimer Disease (414) · Dementia (81) · Cognitive Dysfunction (79) · Neurodegenerative Diseases (19) · Central Nervous System Diseases (16) · Memory Disorders (14) · Supranuclear Palsy, Progressive (13) · Brain Diseases (11) · Psychomotor Agitation (10) · Mental Disorders (9) · Plaque, Amyloid (9) · Nervous System Diseases (8) · Amyloidosis (7) · Inflammation (7)
Nervous System Diseases (423) · Brain Diseases (419) · Central Nervous System Diseases (414) · Neurodegenerative Diseases (412) · Neurocognitive Disorders (411) · Mental Disorders (408) · Dementia (336) · Cognition Disorders (77) · Pathological Conditions, Signs and Symptoms (73) · Neurologic Manifestations (51) · Signs and Symptoms (51) · Neurobehavioral Manifestations (35) · Behavior (21) · Basal Ganglia Diseases (20)
Donepezil (20) · florbetapir (9) · Saline Solution (8) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (7) · vanutide cridificar (7) · saponin QA-21V1 (6) · 3-benzenesulfonyl-8-piperazin-1-ylquinoline (5) · crenezumab (5) · Insulin (4) · Levetiracetam (4) · Sodium Chloride (4) · VX-745 (4) · solanezumab (4) · tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (4) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (3)
Pfizer (16) · Avid Radiopharmaceuticals (12) · Eli Lilly and Company (12) · GlaxoSmithKline (8) · University of Wisconsin, Madison (8) · AbbVie (prior sponsor, Abbott) (5) · Boehringer Ingelheim (5) · Genentech, Inc. (5) · National Institute of Neurological Disorders and Stroke (NINDS) (5) · University of Southern California (5) · University of Washington (5) · Anavex Life Sciences Corp. (4) · Chang Gung Memorial Hospital (4) · Cognition Therapeutics (4) · Columbia University (4)
United States (291) · Canada (55) · Germany (49) · United Kingdom (47) · France (46) · Spain (44) · Australia (29) · Italy (26) · Netherlands (26) · Poland (23) · Sweden (22) · Czechia (19) · South Korea (19) · Japan (17) · Russia (12)
Suzanne Craft, PhD (5) · Bruno Kajiyama, MS (4) · Cynthia M. Carlsson, MD, MS (3) · Gabriella Bottini, Prof. (3) · Laura Gault, MD (3) · Lindsay Burns, PhD (3)
PMID 25918556, PMID 33974419, PMID 39800465, PMID 33189083, PMID 34532852, PMID 25731629, PMID 26967206, PMID 27494299, PMID 29854923, PMID 30558645, PMID 30755255, PMID 31353964, PMID 31710528, PMID 31969177, PMID 32107748, PMID 33646153, PMID 33973646, PMID 34521461, PMID 36627206, PMID 36934371, PMID 36946448, PMID 39166791, PMID 40368603, PMID 40603145, PMID 40667684, PMID 41220869, PMID 41804324, PMID 42063312, PMID 42393277, PMID 12783912, PMID 15883262, PMID 17068314, PMID 17951067, PMID 18204357, PMID 18580589, PMID 18640457, PMID 18672400, PMID 18695053, PMID 19054783, PMID 19664276, PMID 19949163, PMID 20087081, PMID 20350302, PMID 20625270, PMID 20672243, PMID 20837824, PMID 20872778, PMID 20930300, PMID 20978227, PMID 21481640
2009 (10), 2016 (5), 2014 (3), 2005 (2), 2008 (2), 2015 (2), 2019 (2), 2023 (2), K23AG026752 (2), K23AG052633 (2), R21AT003302 (2), R44AG060878 (2), 1RF1AG051514 (1), 2018 (1), 4UH3TR000967-02 (1)